Celldex Therapeutics, Inc.
CLDX
$29.53
$0.993.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 19.71% | 16.12% | |||
| Gross Profit | -19.52% | -17.70% | |||
| SG&A Expenses | 11.74% | 2.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.55% | 13.98% | |||
| Operating Income | -18.39% | -15.28% | |||
| Income Before Tax | -21.29% | -18.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.29% | -18.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.29% | -18.45% | |||
| EBIT | -18.39% | -15.28% | |||
| EBITDA | -18.61% | -15.57% | |||
| EPS Basic | -21.16% | -18.40% | |||
| Normalized Basic EPS | -21.16% | -18.41% | |||
| EPS Diluted | -21.16% | -18.40% | |||
| Normalized Diluted EPS | -21.16% | -18.41% | |||
| Average Basic Shares Outstanding | 0.10% | 0.04% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||